Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24596265 | 0.75 | NPSR1 (0.39) | NPSR1 | |
| SCHEMBL29247375 | 0.72 | DGAT1 (0.37) | NPSR1 | |
| SCHEMBL24596295 | 0.72 | MEN1 (0.37) | DUTMAPK1 | |
| SCHEMBL24434777 | 0.72 | DUT (0.42) | DUTMAPK1SMN1; SMN2 | |
| SCHEMBL31132827 | 0.72 | DUT (0.38) | DUTMAPK1SMN1; SMN2 | |
| SCHEMBL19737998 | 0.70 | NPSR1 (0.43) | MAPK1SMN1; SMN2NPSR1 | |
| SCHEMBL20536296 | 0.69 | DUT (0.38) | DUTSMN1; SMN2 | |
| SCHEMBL31421962 | 0.69 | CA12 (0.39) | DUTNPSR1 | |
| SCHEMBL31421964 | 0.69 | CA12 (0.39) | DUTNPSR1 | |
| SCHEMBL21877947 | 0.68 | DUT (0.32) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| CN-116670144-A | Tricyclic compounds and uses thereof | 南京再明医药有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | DUT 4533/4885MAPK1 1249/4885SMN1; SMN2 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.